Understanding why some endometrial hyperplasia patients don't respond to progesterone treatment
Unravelling mechanisms and novel therapeutic targets for progesterone-resistant endometrial hyperplasia
['FUNDING_R01'] · UNIVERSITY OF MISSOURI-COLUMBIA · NIH-11093422
This study is looking into why some women with complex atypical hyperplasia or endometrial cancer don’t respond well to progesterone treatment, and it aims to find helpful signs that can predict how well they might do with this therapy, all while focusing on ways to help them keep their fertility.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MISSOURI-COLUMBIA (nih funded) |
| Locations | 1 site (COLUMBIA, UNITED STATES) |
| Trial ID | NIH-11093422 on ClinicalTrials.gov |
What this research studies
This research investigates the mechanisms behind progesterone resistance in complex atypical hyperplasia (CAH) and endometrial cancer (EC), which are conditions that can affect women's reproductive health. The study aims to identify biomarkers that predict how well patients will respond to progesterone therapy, a common treatment option. By focusing on fertility-sparing approaches, the research seeks to develop effective treatments that allow women to maintain their fertility while addressing these serious conditions. The methodology includes analyzing biological markers and signaling pathways involved in progesterone resistance.
Who could benefit from this research
Good fit: Ideal candidates for this research are reproductive-aged women diagnosed with complex atypical hyperplasia or endometrial cancer who are seeking fertility-sparing treatment options.
Not a fit: Patients who have already undergone a hysterectomy or are not of childbearing age may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for women with endometrial hyperplasia and cancer, allowing them to retain their fertility.
How similar studies have performed: Previous research has shown promise in understanding hormonal resistance in similar conditions, but this specific approach to progesterone resistance is relatively novel.
Where this research is happening
COLUMBIA, UNITED STATES
- UNIVERSITY OF MISSOURI-COLUMBIA — COLUMBIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KIM, TAE HOON — UNIVERSITY OF MISSOURI-COLUMBIA
- Study coordinator: KIM, TAE HOON
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer therapy, cancer therapy